NIH Funds Slow to Reach Vendors, But MS and Other Instrument Firms May Be First to Benefit, Report Says | GenomeWeb

This story originally ran on Dec. 17.

Instrument firms, including several mass spectrometry firms, have seen little stimulus funding so far and expect such funds not to impact their fourth-quarter earnings results, Thomas Weisel Partners said in an analyst report issued late last week.

However, in the report, the investment firm said that once recipients of the funds start spending the grants, instrument vendors could be "the biggest beneficiaries of the initial funding wave."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.